Mineralys Therapeutics, Inc. MLYS Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s investment proceeds?
- Mineralys Therapeutics, Inc. (MLYS) reported investment proceeds of $302.5M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s investment proceeds changed year-over-year?
- Mineralys Therapeutics, Inc.'s investment proceeds increased by 764.3% year-over-year, from $35M to $302.5M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s investment proceeds?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s investment proceeds has grown at a 104.1% compound annual growth rate (CAGR), from $50M to $425M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.